Trial · NCT02974868
Results by group711
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 711
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 | PF-06651600 | 32.54 | 90% Confidence Interval 25.35 to 39.74 | units on a scale | |
| Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 | PF-06700841 | 50.59 | 90% Confidence Interval 43.15 to 58.02 | units on a scale | |
| Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 | Placebo | 1.41 | 90% Confidence Interval -6.03 to 8.85 | units on a scale | |
| Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants | PF-06651600-AT/AU | 27.59 | 90% Confidence Interval 15.24 to 39.94 | units on a scale | |
| Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants | PF-06700841-AT/AU | 48.42 | 90% Confidence Interval 36.38 to 60.47 | units on a scale | |
| Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants | Placebo-AT/AU | 1.81 | 90% Confidence Interval -11.00 to 14.63 | units on a scale | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Active Non-responders on PF-06651600 | TEAE (All Causalities) | 8 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Placebo Non-responders on PF-06651600 | TEAE (All Causalities) | 12 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Active Non-responders on PF-06700841 | TEAE (All Causalities) | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Placebo Non-responders on PF-06700841 | TEAE (All Causalities) | 10 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Non-Retreated PF-06651600 Responders in the Withdrawal Segment | TEAE (All Causalities) | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Retreated PF-06651600 Responders in the Withdrawal Segment | TEAE (All Causalities) | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Non-Retreated PF-06700841 Responders in the Withdrawal Segment | TEAE (All Causalities) | 6 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Retreated PF-06700841 Responders in the Withdrawal Segment | TEAE (All Causalities) | 9 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Retreated PF-06651600 Responders in the Retreatment Segment | TEAE (All Causalities) | 11 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Retreated Responders on PF-06700841 in the Retreatment Segment | TEAE (All Causalities) | 9 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Active Non-responders on PF-06651600 | TEAE (Treatment Related) | 5 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Placebo Non-responders on PF-06651600 | TEAE (Treatment Related) | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Active Non-responders on PF-06700841 | TEAE (Treatment Related) | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period | Placebo Non-responders on PF-06700841 | TEAE (Treatment Related) | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02974868/results